Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Bristol Myers Squibb Stock Climbs on Alzheimer's Trial Update. What to Know.
The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer's disease.
Bristol Myers must face $6.7 billion lawsuit over delayed cancer drug, US judge rules
A U.S. judge on Monday rejected Bristol Myers Squibb's bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi, by specified deadlines.
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
What Is Happening With BMY Stock?
Bristol Myers Squibb (BMY) is finally showing signs of life. The stock has climbed 7.3% over the last five days, adding roughly $7 billion in market value — pushing its market cap back toward $100 billion.
2 Top Dividend Stocks to Buy and Hold
Bristol Myers Squibb and Johnson & Johnson have had a tough past few years due to several factors. Both companies are looking to right the ship thanks to new product launches.
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.
Will Opdivo and Opdivo Qvantig Drive BMY's Top-Line Growth?
Bristol Myers strengthens its Opdivo franchise with rising demand and strong uptake of Qvantig, leveraging label expansions to sustain revenue growth.
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi (Revised)
Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi
Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
Bristol-Myers Squibb: I See No Catalysts To Break Underperformance
Bristol-Myers Squibb (BMY) faces a severe patent cliff, risking up to 60% of recent revenues as key blockbusters lose exclusivity. BMY's pipeline and recent acquisitions are unlikely to offset revenue declines, with new therapies facing intense competition and limited blockbuster potential. Financial fundamentals are deteriorating, with falling revenue, EBITDA margins, and net income, while high debt and weak free cash flow constrain flexibility.
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
